Evaluation of Snakebite Cases in Assiut Governorate, Egypt (Prospective Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-30

Study Completion Date

2026-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Study the sociodemographic profile of snakebite victims in Assiut Governorate.
2. Portray the clinical profile of snakebite victims admitted to Assiut University , El Eman General Hospital and Assiut General Hospital.
3. Assess the predictors of severity and outcome of cases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Guidelines on Nurses' Awareness Toward HRP and Maternal Near Miss Cases

NCT06262568

High Risk Pregnancy and Maternal Near Miss Cases

RECRUITING

Emergency Obstetric Care Protocol

NCT07248605

Emergency Care Obstetric

NOT_YET_RECRUITING NA

Paperless Parotograph in Evaluation of Labour

NCT03272282

Labor Complication

UNKNOWN

Wide Use of Paperless Partograph in Evaluation of Labour

NCT03276117

Labor Complication Labor Pain

COMPLETED

Outcomes and Trauma Pattern in Penetrating Neck Injuries

NCT04615338

Neck Injuries

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Snake's envenomation is a serious socio-medical problem, which causes considerable mortality and morbidity, with approximately 125,000 deaths worldwide annually. There were 4.5 to 5.4 million bites every year, and of those figures, 40-50% had some clinical disability as a result. Furthermore, the death from such an issue could go somewhere between 80,000 and 130,000 individuals each year. In the Middle East and North Africa, there are over 70,000 snakebites bites each year.

There are many species of snakes, approximately 3,700 species of snakes worldwide only about 15% are venomous belong to the four large families including Viperidae, Colubridae, Elapidae and Atractaspidinae. Two of these toxic species are widespread in Egypt; the family Viperidae and the family Elapidae Egyptian copra Naja Haje.

Snake venoms are complex mixtures consisting of enzymatic components e.g., proteolytic enzymes e.g., serine protease and metalloproteases (SVMPs), non-enzymatic components e.g., cysteine-rich secretory proteins (CRISP), amines, lipids, nucleotides, and carbohydrates. Venoms also contain inorganic cations that are presumed to function as cofactors and include sodium, calcium, potassium, magnesium, and zinc.

Snake venoms are usually classified as hemotoxic or neurotoxic. Snakes of the Viperidae family have venom containing proteins that can disrupt the coagulation cascade, the hemostatic system and tissue integrity. In contrast, neurotoxic venoms, which are typical of the Elapidae snakes, contain several toxins that primarily affect the peripheral nervous system, in particular the neuromuscular junction.

Depending on the species of snakes, manifestations can be localized symptoms of mild pain, progressive edema, ecchymosis, and tissue necrosis and generalized ones as spontaneous bleeding e.g., bleeding per gums, epistaxis, hematuria, vaginal bleeding, hematemesis, hematochezia, hemoptysis, hemolytic anemia and hemolytic jaundice with hemototoxic snake venom. In severe cases patients may develop acute renal, myocardial infarction, disseminated intravascular coagulation, or even death. Ptosis, diplopia, dysphagia, trunk and limbs weakness, and respiratory paralysis which can lead to respiratory failure and apnea with neurotoxic snake venom.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Snakebite Cases Evaluation Clinical and Laboratory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients admitted with a reliable history of snakebite.
* Presence of fang marks and/or signs of local and systemic envenomation.

Exclusion Criteria

* Fake or uncertain snakebites.
* Patients with history of hematological disorders, liver diseases, renal diseases and anticoagulation therapy in the past week.
* Patients who are not willing to participate in the study.

Eligible Sex

ALL

Accepts Healthy Volunteers

No